Emcure Pharma launches new dermatology-focused arm Emcutix Biopharma
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-10-28 10:44 GMT | Update On 2024-10-28 11:19 GMT
Advertisement
Pune: Emcure Pharmaceuticals Limited, an Indian Pharma company, has launched a wholly-owned subsidiary, Emcutix Biopharmaceuticals Limited, focused exclusively on dermatology.
"The Company is set to cater to a growing dermatology segment in India with formation of a wholly-owned subsidiary, Emcutix Biopharmaceuticals Limited," the release stated. As a part of this strategic initiative, Emcure's existing dermatology business will also operate under Emcutix. The newly setup entity plans to significantly expand Emcure’s offerings. The focus will be on building a differentiated product portfolio including first-time launches designed to fulfil the unmet needs of the Indian dermatology market.
The market is seeing strong growth primarily driven by a growing population. As per IQVIA, the Indian dermatology market stands at $1.84 Bn (MAT sales July 2024). The Indian consumers are becoming increasingly conscious of skin health, driving the need for both therapeutic and aesthetic skin care products.
Read also: Emcure Pharma set to launch IPO on July 3
Speaking on the future growth of dermatology, CEO and Managing Director of Emcure Pharmaceuticals Limited, Satish Mehta stated, “The dermatology market in India, is experiencing a significant surge in both value and unit consumption. Emcure is well-positioned to cater to the unmet needs of the Indian market. With a dedicated entity, Emcure aims to concentrate on developing and introducing both prescription and consumer dermatology solutions.”
Emcutix will be spearheaded by G. Sathya Narayanan, who brings with him over three decades of extensive experience in the dermatology sector, with his last stint as the Managing Director of Galderma for South Asia (including India). His notable career includes building some of the most iconic brands in prescription, consumer, and aesthetic dermatology.
Commenting on his new role with Emcutix, Sathya Narayanan said, “Emcutix represents a unique opportunity with derma care solutions for healthcare professionals, patients and consumers by developing a differentiated dermatology portfolio. Building on Emcure’s legacy of innovation, I look forward to building a portfolio of products that will make a meaningful difference in skin health in India.”
Established in 1981, Emcure is an Indian pharmaceuticals company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.